 Evoke Pharma, Inc. EVOK, a specialty pharmaceutical company focused on treatments for gastrointestinal GI diseases, today announced that on November 12, 2019, it received notification from the Listing Qualifications Department of the Nasdaq Stock Market indicating that the Company has been granted an additional 180-day grace period to regain compliance with the minimum 1.00 bid price per share requirement of Nasdaqs Marketplace Rule 5550a2. In accordance with the rule, the Company was eligible for the additional compliance period because it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement. 